In last December, The retail sales of Inavir in Japan was more than 1.3millon units, higher than tamiflu again. The retail sales of relenza was more than 0.5milllion units. The royalties from relenza and inavir should be good for last quarter and coming quarter.
- Forums
- ASX - By Stock
- BTA
- something's happening at the station